팔벨라 테라퓨틱스(PVLA)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $150.56 (-2.44%), 시가총액 $1.63B.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
팔벨라 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
팔벨라 테라퓨틱스의 현재 주가는 $150.56 (-2.44%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
팔벨라 테라퓨틱스의 시가총액은 약 $1.63B입니다.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.